New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, Artizan Biosciences is raising $18,877,921.00 in new funding. Sources indicate as part of senior management President, Bridget Martell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Artizan Biosciences
Artizan Biosciences, Inc. is a biotechnology company creating a new class of transformative precision therapeutics that target and block the root causes of diverse, serious diseases triggered by intestinal inflammation. Founded with IgA-SEQ technology and preeminent immunobiology expertise from Yale University, Artizan leverages the microbiome as a drug discovery tool to identify and characterize microbial drivers of disease. Capable of using both novel small molecule and monoclonal antibody approaches, the company modulates intestinal imbalances by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract. This unique approach allows Artizan to design compounds that arrest the inflammatory cascade within precise patient subsets in certain cancers and gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. The company’s lead program in inflammatory bowel disease is nearing the clinic and is validated by strategic partnerships with Biohaven Pharmaceuticals, Brii Biosciences, and the Crohns & Colitis Foundation. Artizan is based in New Haven, CT.

To learn more about Artizan Biosciences, visit http://artizanbiosciences.com/

Contact:
Bridget Martell, President
203-457-3486
bridget.martell@artizanbiosciences.com
https://www.linkedin.com/in/bridget-martell-7309695/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved